tiprankstipranks
Alvotech and Advanz Pharma Partner on Biosimilars
Company Announcements

Alvotech and Advanz Pharma Partner on Biosimilars

Alvotech (ALVO) has released an update.

Don't Miss Our Christmas Offers:

Alvotech has partnered with Advanz Pharma to commercialize two biosimilar candidates to Eylea® in Europe, aiming to provide more affordable biologic treatments for eye disorders. The deal grants Advanz Pharma exclusive rights to commercialize these biosimilars across Europe, with Alvotech handling development and supply. This collaboration is part of Alvotech’s strategy to be a global leader in biosimilars, offering cost-effective alternatives for high-demand medicines.

For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAlvotech Reports Strong Revenue Growth in 2024
TipRanks Auto-Generated NewsdeskAlvotech Showcases Strong Financial Growth and Expansion
Catie PowersALVO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App